##plugins.themes.academic_pro.article.main##

Abstract

The landscape of cancer treatment has dramatically changed over the last four decades. The age when surgery and radiotherapy were the only effective way to fight tumour growth has ended. A complex scenario where the molecular features of tumours seem to be the cornerstone of any therapy is now emerging. Small molecule drugs are being intensively pursued as new anticancer therapeutics. Cancer treatment has benefited significantly from progress in understanding how to target kinases with small molecules that were found to be correlated with the disease because many kinases have been found to be intimately involved in the processes leading to tumour cell proliferation and survival. This review provides an overview on the different approaches to cancer treatment including the role of classic cancer therapies that is - surgery, radiation, chemotherapy and endocrine therapy and then an up-date on the novel, up-growing therapies of the current targeted therapy - including new monoclonal antibodies, small molecules, antiangiogenics and viral therapy. Finally, few words about the development of new biomarkers and how it should rule and determine the future of therapeutic research in cancer. 

Keywords

Cancer therapy chemotherapy biomarkers targeted therapy virotherapy antiagiogenesis monoclonal antibodies

##plugins.themes.academic_pro.article.details##

Author Biographies

Md. Motahar Hossain, Colonel Malek Medical College, Manikganj

Associate Professor of Medicine, Colonel Malek Medical College, Manikganj

Md. Kamrul Hasan, Colonel Malek Medical College, Manikganj

Department of Haematology, Colonel Malek Medical College, Manikganj

How to Cite
1.
Hossain MM, Hasan MK. Recent Advances in Cancer Treatment: A Review. CMMCJ [Internet]. 2019 Jul. 31 [cited 2022 Aug. 13];2(02):31-45. Available from: https://cmmcj.org/index.php/cmmcj/article/view/28

##journal.references##

  1. World Health Organization. Cancer. 12 September 2018. Retrieved 19 December 2018.
  2. National Cancer Institute. Defining Cancer. 17 September 2007. Retrieved 28 March 2018.
  3. American Cancer Society. The History of Cancer. 2009.
  4. Institut Jules Bordet (Association Hospitalière de Bruxelles - Centre des Tumeurs de ULB). The History of Cancer. Retrieved 2010-11-19. Bordet. be. Retrieved 2011-01-29.
  5. Moss and Ralph W. Galen on Cancer. Cancer Decisions. 2004. Archived from the original on July 16, 2011.
  6. Karpozilos A and Pavlidis N. The treatment of cancer in Greek antiquity. European Journal of Cancer. 2004;40(14):2033–2040.
  7. Uddin AK, Khan ZJ, Islam J and Mahmud AM. Cancer care scenario in Bangladesh. South Asian. J Cancer. 2013;2:102–104.
  8. Noronha V, Tsomo U, Jamshed A, Hai MA, Wattegama S, Baral RP, Piya M and Prabhash KA. Fresh look at oncology facts on south central Asia and SAARC countries. South Asian J Cancer. 2012;1:1–4.
  9. Urruticoechea A, Alemany R, Balart J, Villanueva A, Viñals F and Capellá G. Recent Advances in Cancer Therapy: An Overview. Current
  10. Pharmaceutical Design. 2010;16(1).
  11. Xu G and McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res. 2001;7:3314–3324.
  12. Toloudi M, Apostolou P, Chatziioannou M, Kourtidou E, Vlachou I, Mimikakou G, Chlichlia A and Papasotiriou I. Recent Developments in Cancer Treatment: A Review. Pharmaceut Reg Affairs. 2014;S1:001.
  13. Padma VV. An overview of targeted cancer therapy. Biomedicine (Taipei). 2015;5(4):19.
  14. Figueras J, Torras J, Valls C, Llado L, Ramos E, Marti-Rague J, Serrano T and Fabregat J. Surgical resection of colorectal liver metastases in patients with expanded indications: a singlecenter experience with 501 patients. Dis Colon Rectum. 2007;50(4):478-488.
  15. Oyama T, Tomori A, Hotta K, Morita S, Kominato K, Tanaka M and Miyata Y. Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol. 2005;3:S67–70.
  16. Surgical oncology for cancer: Procedures and recovery programs. CTCA online news. 2019. myCTCA.com.
  17. Saglam R, Muslumanoglu AY, Tokatli Z, Ça?kurlu T, Sarica K, Ta?çi AI, Erkurt B, Süer E, Kabakci AS, Preminger G, Traxer O and Rassweiler JJ. A new robot for flexible ureteroscopy: development and early clinical results (IDEAL Stage 1-2b). Eur Urol. 2014;66:1092–1100.
  18. Barbash GI and Glied SA. New technology and health care costs: the case of robotic-assisted surgery. N Engl J Med. 2010;363:701–704.
  19. Yaxley JW, Coughlin GD, Chambers SK, Occhipinti S, Samaratunga H, Zajdlewicz L, Dunglison N, Carter R, Williams S, Payton DJ,
  20. Perry-Keene J, Lavin MF and Gardiner RA. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet. 2016;388:1057–1066.
  21. deCuba EMV, Kwakman R, Knol DL, Bonjer HJ, Meijer GA and teVelde EA. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies. Cancer Treatment Reviews. 2013;39(4):321-327.
  22. Hilgers FJ and Schouwenburg PF. A new lowresistance, self-retaining prosthesis (Provox) for voice rehabilitation after total laryngectomy. Laryngoscope. 1990;100:1202-1207.
  23. Kapila M, Deore N, Palav RS, Kazi RA, Shah RP and Jagade MV. A brief review of voice restoration following total laryngectomy. Indian
  24. journal of cancer. 2011;48(1):99-104.
  25. Rachit D, Shah and Thomas A. D’Amico. Modern impact of video assisted thoracic surgery. J Thorac Dis. 2014;6(6):631-636.
  26. Barton MB, Frommer M and Shafiq J. Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncol. 2006;7:584–595.
  27. Barton MB, Jacob S, Shafiq J, Wong K, Thompson SR, Hanna TP and Delaney GP. Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiother Oncol. 2014;112:140–144.
  28. Tyldesley S, Delaney G, Foroudi F, Barbera L, Kerba M and Mackillop W. Estimating the need for radiotherapy for patients with prostate, breast, and lung cancers: verification of model estimates of need with radiotherapy utilization data from British Columbia. Int J Radiat Oncol Biol Phys. 2011;79:1507–1515.
  29. Delaney G, Jacob S, Featherstone C and Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104(6):1129-1137.
  30. Alterio D, Franco P, Numico G, Licitra L, Cossu Rocca M, Ferrari A, Pinto C, Russi EG, Ricardi U and Fossa JBA. Non-surgical organ preservation strategies for locally advanced laryngeal tumors: What is the Italian attitude? Results of a national survey on behalf of AIRO and AIOM. Med Oncol. 2016;33:76.
  31. Mak RH, Zietman AL, Heney NM, Kaufman DS and Shipley WU. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int. 2008;102:1345–1353.
  32. Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL and Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333:1456–1461.
  33. Chow E, Zeng L, Salvo N, Dennis K, Tsao M and Lutz S. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol). 2012;24:112–124.
  34. Jackson SP and Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–1078.
  35. Budach W, Bölke E and Matuschek C. Hypofractionated radiotherapy as adjuvant treatment in early breast cancer: a review and
  36. meta-analysis of randomized controlled trials. Breast Care (Basel). 2015;10:240–245.
  37. Garibaldi C, Alicja B Fossa J, Marvaso G, Dicuonzo S, Rojas DP, Cattani F, Starzy?ska A, Ciardo D, Surgo A, Leonardi CM and Ricotti R.
  38. Recent advances in radiation oncology. E cancer medical science. 2017;11: 785.
  39. Veldeman L, Madani I, Hulstaert F, DeMeerleer G, Mareel M and DeNeve W. Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies. Lancet Oncol. 2008;9:367–375.
  40. Jin JY, Wen N, Ren L, Hurst GC and Chetty IJ. Advances in treatment techniques: arc-based and other intensity modulated therapies. Cancer J. 2011;17:166–176.
  41. Potters L, Kavanagh B and Galvin J. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010;76:326–332.
  42. Adler JR, Chang SD, Murphy MJ, Doty J, Geis P and Hancock SL. The Cyberknife: a frameless robotic system for radiosurgery. Stereotact Funct Neurosurg. 1997;69:124–128.
  43. Solberg TD, Medin PM, Ramirez E, Ding C, Foster RD and Yordy J. Commissioning and initial stereotactic ablative radiotherapy experience with Vero. J Appl Clin Med Phys. 2014;15:4685.
  44. Durante M, Orecchia R, Loeffler JS. Chargedparticle therapy in cancer: clinical uses and future perspectives. Nat Rev Clin Oncol.
  45. ;14(8):483–495.
  46. Mohan R and Grosshans D. Proton therapy– present and future. Adv Drug Deliv Rev. 2017;109:26–44
  47. Jaffray DA. Image-guided radiotherapy: from current concept to future perspectives. Nat Rev Clin Oncol. 2012. 2012;9:688–699.
  48. Verellen D, DeRidder M, Linthout N, Tournel K, Soete G and Storme G. Innovations in image-guided radiotherapy. Nat Rev Cancer.
  49. ;7:949–960.
  50. Ferrara N and Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005; 438(70):967-974.
  51. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F and Bismuth H. Tumor progression while on chemotherapy:
  52. a contraindication to liver resection for multiple colorectal metastases?. Ann Surg. 2004;240(6):1052-1061.
  53. Alam A, Farooq U, Singh R, Dubey VP, Kumar S, Kumari R, Naik KK, Tripathi BD and Dhar KL. Chemotherapy Treatment and Strategy Schemes: A Review. Open Acc J of Toxicol. 2018;2(5):001-005.
  54. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A and McLennan MT. Nitrogen mustard therapy: use of methylbis
  55. (?-chloroethyl) amine hydrochloride and tris (?-chloroethyl)amine hydrochloride for Hodgkin’s disease, lymphosarcoma, leukemia,
  56. and certain allied and miscellaneous disorders. JAMA. 1946;132:126–132.
  57. Kerbel RS and Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4(6):423-436.
  58. Hanahan D, Bergers G and Bergsl E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105(8):1045-1047.
  59. Bailar JC and Gornik HL. Cancer undefeated. N Engl J Med. 1997;336(22):1569-1574.
  60. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
  61. Sawyers C. Targeted cancer therapy. Nature. 2004;432:294-297.
  62. Jensen BP and Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355–365.
  63. Workman P. On the challenges of cancer drug development. Drug Disc Today. 2003;8:775–777.
  64. Sawyers CL. Rational therapeutic intervention in cancer: kinases as drug targets. Curr Opin Gen Develop. 2002;12:111–115.
  65. Bertram JS. The molecular biology of cancer. Mol Aspects Med. 2001;21:167–223.
  66. National Cancer Institute. Targeted Therapies for Breast Cancer Tutorial. Archived from the original on 29 March 2011. Retrieved19 April 2011.
  67. Le XF, Pruefer F and Bast R. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle. 2005;4(1):87–95.
  68. Yarden Y and Sliwkowski MX. Untangling the Erb B signaling network. Nat Rev Mol Cell Biol. 2001;2(2):127-137.
  69. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-712.
  70. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M,
  71. Moynahan ME, Moasser M, Sklarin N, Dickler M, D’Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L and Hudis CA. Weekly
  72. trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype andgene amplification. J Clin Oncol. 2001;19(10):2587-2595.
  73. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L. Use of chemotherapy plus a monoclonal anti-body against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med. 2001;344(11):783-792.
  74. Annelies HB, Beijnen JH and Schellens JHM. Trastuzumab. Oncologist. 2011;16(6):800–810.
  75. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S and Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-2743.
  76. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Cutsem
  77. VE. Cetuximab monotherapy and cetuximab plusirinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
  78. ;351(4):337-345.
  79. Jakobovits A, Amado RG, Yang X, Roskos L and Schwab G. From Xeno Mouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol. 2007;25(10):1134-1143.
  80. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK,
  81. Averbuch SD, Ochs JJ and Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149-2158.
  82. Deininger MW. Milestones and monitoring in patients with CML treated with imatinib. Education Program Book; 50th ASH Conference. 2008;pp. 419–426.
  83. Lydon NB and Druker BJ. Lessons learned from the development of imatinib. Leuk Res. 2004;28(Suppl 1):S29-38.
  84. Deininger MWN and Druker BJ. Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib. Pharmacol Rev. 2003;55:401–423.
  85. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad TG, Matsuzawa Y, Kanakura Y, Shinomura Y and Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577-580.
  86. FDA Highlights and Prescribing Information for Gleevec (imatinib mesylate)(PDF). Archived (PDF) from the original on 13 September 2014.
  87. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8(4):286-298.
  88. Bishton M, Kenealy M, Johnstone R, Rasheed W and Prince HM. Epigenetic targets in hematological malignancies: combination
  89. therapies with HDACis and demethylating agents. Expert Rev Anticancer Ther. 2007;7(10):1439-1449.
  90. Hanahan D and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-564.
  91. Bergers G and Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401-410.
  92. Folkman J and Ingber D. Inhibition of angiogenesis. Semin Cancer Biol. 1992;3(2):89-96.
  93. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R and Harris AL. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997;57(5):963-969.
  94. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
  95. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone formetastatic breast cancer. N Engl J Med. 2007;357(26):2666-2676.
  96. Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikstrom A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts
  97. JG, Morando C, Loundou A, Groen HJM and Rittmeyer A. Maintenance bevacizumabpemetrexed after first-line cisplatin-emetrexedbevacizumab for advanced nonsquamous nonsmall-cell lung cancer: Updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Annals of Oncology. 2014;25(5):1044–1052.
  98. FDA clears Genentech drug for kidney cancer. San Francisco Chronicle. August 2, 2009. Archived from the original on September 30, 2010.
  99. Khasraw M, Ameratunga MS, Grant R, Wheeler H and Pavlakis N. Antiangiogenic therapy for high-grade glioma. The Cochrane Database of Systematic Reviews. 2014;(9):CD008218.
  100. Pazdur R. FDA Approval for Bevacizumab. 2009. National Cancer Institute. Archived from the original on 2010-01-10. Retrieved 2010-05-11.
  101. Research, Center for Drug Evaluation and Approved Drugs - FDA approves bevacizumab in combination with chemotherapy for ovarian cancer. 2018.
  102. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R and Pazdur R. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13(5):1367-1373.
  103. Lago LD, D’Hondt V and Awada A. Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors. The Oncologist. 2008;13(8):845-858.
  104. Al-Husein B, Abdalla M, Trepte M, DeRemer DL and Somanath PR. Anti-angiogenic therapy for cancer: An update. Pharmacotherapy.
  105. ;32(12):1095–1111.
  106. Motalleb G. Virotherapy in Cancer. Iran J Cancer Prev. 2013;6(2):101–107.
  107. Bilsland AE, Spiliopoulou P and Evans TRJ. Virotherapy: cancer gene therapy at last? F1000Res. 2016;5:Online Version 1.
  108. Ferguson MS, Lemoine NR and Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Advances in Virology. 2012;Article ID 805629: 1–14. http://dx.doi.org/10.1155/2012/805629
  109. Melcher A, Parato K, Rooney CM and Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Molecular Therapy. 2011;19 (6):1008–1016.
  110. Donnelly OG, Errington-Mais F, Prestwich R, Harrington K, Pandha H, Vile R and Melcher AA. Recent clinical experience with oncolytic
  111. viruses. Current Pharmaceutical Biotechnology. 2012;13(9):1834–1841.
  112. Sheridan C. First oncolytic virus edges towards approval in surprise vote. Nature Biotechnology. 2015;33(6):569–570.
  113. Hematology/Oncology (Cancer) Approvals & Safety Notifications. U.S. Food and Drug (FDA) Administration. Last Updated: 03/19/2019
  114. DeVita, Vincent T, Hellman, Samuel, Rosenberg and Steven A (Eds). Cancer: principles & practice of oncology. Philadelphia: Lippincott. 2005;ISBN0-7817-4865-4868.
  115. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001(1):CD000486.
  116. Smith IE and Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003.348(24):2431-2442.
  117. Eiermann W, Paepke S, Appfelstaedt J, Llombart- Cussac A, EreminJ, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M and Borgs M. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527-1532.
  118. Carlson RW, Hudis CA and Pritchard KI. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw. 2006;4(10):971-979.
  119. Kerbel RS and Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4(6):423-436.
  120. Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J and Hehlmann R. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015;29(5):1123-1132.
  121. Chatterjee SK and Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncology (online). 2005:37-50. PMID:16555974. DOI: 10.1517/14796694.1.1.37.
  122. Gold P and Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965;121:439.
  123. Mungan NA, Vriesema JLJ, Thomas CMG, Kiemeney LALM and Witjes JA. Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer. Urology. 2000;56:787–792.
  124. Bao L, Loda M, Janmey PA, Stewart R, Anand-Apte B and Zetter BR. Thymosin ? 15: a novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nature Med. 1996;2(12):1322–1328.
  125. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C and Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–792.
  126. Barbieri F, Lorenzi P, Ragni N, Schettini G,·Bruzzo C,·Pedullà F and Alama A. Over expression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Oncology. 2004;66(4):310–315.
  127. Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, White S, Bird CC and Wyllie AH. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene. 1996;12:2641–2649.
  128. Niklinski J, Niklinski W, Laudanski J, Chyczewska E and Chyczewska L. Prognostic molecular markers in non-small cell lung cancer.
  129. Lung Cancer. 2001;34(Suppl. 2):S53–S58.
  130. Isobe N, Onodera H, Mori A, Shimada Y, Yang W, Yasuda S, Fujimoto A, Ooe H, Arii S, Kitaichi M and Imamura M. Caspase-3 expression in human gastric carcinoma and its clinical significance. Oncology. 2004;66(3):201–209.